At the risk of being glib: in pharmaceutical manufacturing, there’s "commercial ready" and "commercial ready."
Some in the industry use the term very loosely, using some internally defined criteria to deem a process ready to make a commercial batch. Others will use it a bit more concretely, saying a process is "commercial ready" because it has been validated or used to produce a single commercial-scale batch. Sometimes facilities are dubbed “commercial ready” simply because they can handle the scale of a commercial batch.
Those are all useful benchmarks, but sponsors need to raise their expectations: an oral solid dosage (OSD) product is truly commercial ready only when the process and facility have demonstrated the capability and capacity to produce the tablet or capsule under the demands of long-term commercial supply.
Here’s how sponsors should set expectations in defining commercial readiness.
Six tests for commercial readiness
- A validated, repeatable process. The process should be demonstrated to consistently produce tablets or capsules that meet established quality specifications. Commercial manufacturing requires repeatability, not simply proof that a process can work once.
- Supply chain redundancy. The pandemic exposed supply-chain weaknesses across industries, and regular drug shortages have persisted every since. A commercial product can be vulnerable to a single raw-material supplier, specialized component, or logistics route. Manufacturers must understand where potential supply-chain bottlenecks exist and have qualified alternatives or contingency plans.
- Adequate release capacity. Manufacturing capacity is just the beginning. Production schedules depend on every element keeping pace, including quality control testing, review, and batch release. A manufacturer can have available production equipment and still create delays if release processes become the constraint.
- Packaging that scales. Bottle configurations, labeling, serialization requirements, and other packaging needs should be capable of supporting forecast commercial volumes without creating a new bottleneck after the product leaves the manufacturing line.
- Sustainability beyond launch. Commercial readiness has to include stability support, with programs that provide ongoing confidence in product quality throughout its shelf life.
- Product review systems. Long-term sustainability needs regular monitoring through annual product reviews to help identify trends and ensure the manufacturing process remains under control over time.
CDMOs that outperform
So, how do you choose a contract manufacturer that can support your product reliably throughout its commercial lifecycle?
Look deeper than equipment and nominal production capacity to the systems surrounding the manufacturing processes. Capability isn’t the same as readiness, and the right partner will be able to demonstrate how it holistically manages validation, materials, testing and release, packaging, stability, and ongoing quality oversight.
At UPM Pharmaceuticals, commercial manufacturing is built around the transition from clinical production to validated, repeatable processes for long-term supply. We support sponsors beyond launch with commercial OSD manufacturing, technology transfer and scale-up, analytical and stability testing, packaging, and ongoing quality support, including annual product reviews.
If you are evaluating whether your tablet or capsule is truly commercial ready, ask UPM what commercial readiness should look like for your product.